• Asian Pacific Journal of Cancer Prevention
• /
• 제13권6호
• /
• pp.2669-2673
• /
• 2012

Purpose: Pancreatic carcinoma is one of the most malignant tumors of the alimentary system, with relatively high incidence rates. The purpose of this study was to assess the efficacy and safety of two regimens for advanced pancreatic carcinoma: continuous transarterial infusion versus systemic venous chemotherapy with gemcitabine and 5-fluorouracil. Methods: Of the 48 patients with advanced pancreatic carcinoma receiving chemotherapy with gemcitabine and 5-fluorouracil, 24 received the selective transarterial infusion, and 24 the systemic chemotherapy. For the continuous transarterial infusion group (experimental group), all patients received gemcitabine 1000 mg/$m^2$, given by 30-minute transarterial infusion, on day 1 of a 4-week cycle for 2 cycles, and a dose of 600 mg/$m^2$ 5-fluorouracil was infused on days 1~5 of a 4-week cycle for 2 cycles. For the systemic venous group (control group), gemcitabine and 5-fluorouracil were infused through a peripheral vein, a dose of 1000 mg/$m^2$ gemcitabine being administrated over 30 min on days 1 and 8 of a 4-week cycle for 2 cycles, and a dose of 600 mg/$m^2$ 5-fluorouracil was infused on days 1~5 of a 4-week cycle for 2 cycles. The effectiveness and safety were evaluated after 2 cyclesaccording to WHO criteria. Results:The objective effective rate in transarterial group was 33.3% versus 25% in the systemic group, the difference not being significant (P=0.626). Clinical benefit rates(CBR) in the transarterial and systemic groups were 83.3% and 58.3%, respectively (P=0.014). The means and medians for survival time in transarterial group were higher than those of the systemic group (P < 0.005). at the same time, the adverse effects did not significantly differ between the two groups (P > 0.05). Conclusion: Continuous transarterial infusion chemotherapy with gemcitabine and 5-fluorouracil could improve clinical benefit rate and survival time of patients with advanced pancreatic carcinoma, compared with systemic venous chemotherapy. Since adverse effects were limited in the transarterial group, the regimen of continuous transarterial infusion chemotherapy can be used more extensively in clinical practice. A CT and MRI conventional sequence can be used for efficacy evaluation after chemotherapy in pancreatic carcinoma.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권12호
• /
• pp.7635-7638
• /
• 2013

Background: Sperm-associated antigen 9 (SPAG9) has been recently proposed as a novel biomarker for early diagnosis of several human tumors, including ovarian, cervical and breast cancers. Its clinical value remains to be clarified for endometrial cancer (EC). In this study, we investigated the utility of serum SPAG9 levels in diagnosis of EC and its association with important clinicopathological parameters. Materials and Methods: This cross-sectional study was performed at a tertiary women's referral center in Ankara, Turkey. Preoperative serum samples were collected from patients surgically treated for endometrial cancer between June 2012-April 2013. Similar aged women with a biopsy proven benign endometrium were used as controls. Serum SPAG9 levels were measured with an enzyme-linked immunosorbent assay (ELISA) method and assessed for links with clinicopathological factors. Receiver operating characteristic (ROC) curve analysis was performed to assess power of SPAG9 levels for EC prediction. P values less than 0.05 were considered statistically significant. Results: A total of 63 women with EC and 27 with benign endometrium were included in the study. Mean age in the EC group was $58.7{\pm}1.1$. Median SPAG9 levels in the EC and control groups were 18.3 (range, 12.7-53.8) and 14.1 (range, 4.3-65.3), respectively (p<0.001). A cut-off value of 17 ng/ml for SPAG9 predicted presence of malignant endometrium with 74% sensitivity and 83% specificity [Area under curve (AUC)=0.82, p<0.001]. SPAG9 levels did not demonstrate any significant association with histological type, FIGO stage, tumor grade, size, myometrial invasion, lymphovascular space invasion, cervical involvement, adnexal involvement, peritoneal cytology or lymph node status (all p>0.05). Conclusions: Testing for SPAG9 may be useful for early detection of EC in asymptomatic high-risk women. Its role in post-treatment follow-up and early detection of recurrence should be assessed in future trials.

• 한국콘텐츠학회논문지
• /
• 제15권9호
• /
• pp.411-417
• /
• 2015

Liver CT 검사에서 간세포암과 간혈관종의 구별은 악성종양과 양성종양을 구별하여 치료방법을 결정하는 것에 있어서 중요한 검사 방법 중 하나이다. 현재 사용되는 방법은 전문의의 주관적인 해석에 의해 판독이 이루어지고 있으며, 추가적인 해석을 위해 본 연구에서는 객관적인 방법을 제시하고자 한다. 조영제 주입 후 검사시간은 조영주입전기(Pre), 동맥기(35sec), 문맥기(70sec), 지연기(180sec)로 하였다. 조영증강패턴변화(Enhancement Pattern) 에서 간세포암의 일반적인 패턴변화는 26.6% 로 관찰 되었다. 간혈관종의 일반적인 패턴변화는 16.6%로 관찰 되었다. 간세포암과 간혈관종의 HU(Hounsfield unit)값 변화를 관찰하기 위해 각각의 시간별 평균값과 표준편차를 확인한 결과 Lesion부위의 artery-portal차이가 가장 큰 것으로 나타났다. (간세포암 $19.76{\pm}23.52$, 간혈관종 $60.23{\pm}29.43$). 간세포암 에서 76.6%, 간혈관종 에서 80.0%가 일치하게 나타났다. 본 연구를 통해 HCC와 HH의 객관적 분석 지표로 HU값 을 제안하고 분석방법을 임상에 사용 한다면 진단에 도움을 줄 것이다.

• 대한약리학회지
• /
• 제29권2호
• /
• pp.283-295
• /
• 1993

일부 malignant tumor에 Pt-complex의 임상 응용 과정에서 신장독성등의 심한 부작용이 문제점으로 지적되고 있다. 이 연구에서는 기존의 cisplatin보다 항암효과는 우수하면서, 부작용을 감소시킨 새로운 Pt-complex의 개발에 역점을 두었다. 본 연구에서는 합성한 Pt (II) complex는 carrier ligand로서 1, 2-diaminocyclohexane (dach)을 사용하였고, leaving group으로는 diphosphine류인 1, 3-bis (diphenylphosphine)의 propane (DPPP) 및 ethane (DPPE)을 도입하였으며, 물에 대한 용해도를 높이기 위해 dinitrate로 만들었다. 새로이 합성한 [Pt (II)-(trans-1-dach)(DPPP)] $(NO_3)_2$ 과 [Pt (II)(trans-1-dach)(DPPE)] $(NO_3)_2$ 는 원소 분석, IR 및 $^{13}C-NMR$ 분석 data에 의하여 위의 물질임이 확인되었다. KHPC-001과 KHPC-002는 MTT assay method에 의한 항암활성 연구를 통하여 P-388, L-1210 lymphocytic leukemia cell에서 항암효과가 인정되었으며, 이 항암효과는 대조 약물로 사용된 cisplatin에 비하여 우수하였다. KHPC-001과 KHPC-002는 토끼의 신세뇨관 세포와 인체의 신피질 세포를 이용한 cytotoxity 및 thymidine 섭취율과 인체 신피질 조직 배양을 이용한 glucose consumption 실험을 통하여 모두 cisplatin보다 신장독성이 현저히 감소되었다. 이상의 결과로 보아 Pt (II) complex는 carrier ligand와 leaving group의 선택에 따라 항암활성의 증가와 신독성의 감소를 일으키는 요인으로 보여지며, 이 연구에서 만들어진 두 Pt (II) complex는 앞으로 다각적인 검토를 거쳐 새로운 anticancer chemotherapeutic agent로 개발될 가능성이 있을 것으로 생각된다.

• 대한방사선치료학회지
• /
• 제18권2호
• /
• pp.75-80
• /
• 2006

목 적: 방사선치료에 있어 종양조직이나 정상조직의 정확한 선량계산은 치료의 성패를 좌우하는 가장 큰 요인이다. 이로 인해 방사선치료계획은 컴퓨터 단층 영상의 재구성을 통한 불균질 조직에 선흡수계수를 밀도로 변환하여 CT 번호에 의한 선량 보정이 유효하게 이루어지고 있다. 대상 및 방법: 이에 본 연구는 불균질 조직등가 팬톰을 제작하여 현재 사용 중인 방사선 치료 계획시스템을 이용한 CT 번호의 측정과 질량밀도를 계산하여 물을 기준으로 상대값을 구하였다. 또한 실제 방사선 조사 시 측정된 선량(nC)과 CT영상을 이용한 치료계획 시 선량(PDD)을 상대적으로 비교함으로써 실제 CT 번호를 이용한 불균질 조직의 보정에 대한 유용성과 정확성을 평가하고자 한다. 결 과: 측정결과 CT 번호를 이용하여 계산된 조직등가물질의 질량밀도와 실제 질량밀도는 $0.005{\sim}0.069g/cm^3$의 차이를 보였으며, 방사선 치료계획 시 심부선량(PDD)과 방사선 치료 장치로 조사하여 측정된 선량의 상대오차는 $-2.8{\sim}+1.06%$로 3% 이내의 유효범위이내의 결과를 얻었다. 결 론: 본 실험은 CT 영상을 이용한 불균질 조직의 보정에 대한 유용성을 확인할 수 있었고, 방사선 치료 계획 장치의 정도 관리(Quality Assurance; QA)의 기본 틀을 제공할 수 있을 것으로 사료된다.

• Journal of Chest Surgery
• /
• 제30권7호
• /
• pp.701-707
• /
• 1997

그동안 폐암의 발생에 관여하는 여러가지 유전자의 이상이 보고되어 왔으나 모든 종류의 폐암에서 보이는 비억제적 성장(unconkolle6 growth)을 대변할 수 있는 유전자적 종양 표시자(molecular tumor marker)는 보고된 바 없었다. 최근 유전자(chromosome)의 말단부에 위치한 특이한 구조인 telomere가 세포의 노화나 증식정도 (proliferative activity)에 따라 그 구조, 특히 TrAGGG 반복 구조가 변한다는 것이 알려진 바 있다. 따라서 telomere의 반복 구조를 만드는 효소인 telomerase의 활성도는 대상 세포의 증식 상황이나 증식 가능성을 나타내는 표시 자로서의 기능이 있다고 추정된다. 따라서 이는 종양의 진단은 물론 대상 환자의 향후 예후를 판 단하는 데도 좋은 지표로 이용될 수 있다. 12개의 다양한 비소세포폐암 세포주와 수술로 적출된 41명의 비세포계암 환자의 종양 조직에 대해 nROolymerase chain reaction)을 기초로 한 TRAP assay를 이용하여 telomeiase활성도를 측정하였다. 대조군으로는 동시에 적출된, 종양으로부터 가장 먼 위치의 정상 폐조직을 이용하였다. 12개 전 종양 세포주는 물론 대부분의 종양 조직(94%)에서, 성별, 연령, 세포 병리학적 subtype, 암기(stage) 등과 관련이 언이, telomerase의 활성도가 측정되었으며 정상이라고 간주된 조직에서는 5명으로 부터 채취한 조직에서만 미약하게 telomerase활성도가 관찰되었다. 예후에 연관지어 telomerase활성도의 의미는 telmerase활성도가 보이지 않는 종글이 극히 적었고 또한 추적 관찰 기간이 짧아 판정할 수 없었다. Telomere의 길이의 변화는의미를 판정키 어려웠다. 이상의 결과는 비소세포폐암에 있어 telomerase활성도의 변화가 암발생에 아주 중요한 과정일 수 있다는 추정을 가능하게 하며 telomerase활성도의 측정이 종양의 진 단에 유용하게 이용될 수 있음을 확인시켜 주는 것이라 사료된다.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• 제26권5호
• /
• pp.455-461
• /
• 2000

Malignant tumors of the head and neck frequently require treatment with both radiotherapy and surgery. Reconstruction of the defect in previously irradiated field is a challenge to surgeon, who must produce both a functional and an esthetic result. Hyperbaric oxygen therapy(HBO) has been used in an attempt to reduce the deleterious effects of radiation. But the issue of whether prior irradiation and HBO of the recipient site of a free flap affects the result of reconstruction continues to generate controversy. So, the effects of irradiation and hypergbaric oxygen therapy on microvascular anastomosis was evaluated in an experimental study in femoral vessels of rats. The experimental groups were divided into 3 groups, contorol group, irradiation group, and irradiation and HBO group. Preoperative irradiation was delivered in the left groin field with single dose corresponding 2,000cGy and total 48 hours of HBO was given 100% oxygen at 2.4 atmosphere for 4 weeks. The femoral vessels of 60 rats were anastomosed after irradiation and HBO treatment. Three days, 1 week, 2 weeks and 4 weeks after surgery, the femoral vessels were evaluated for patency and histopathologic changes. There was no notable effect of irradiation on patency of femoral vessels in rats and the radiation effects were obvious on histological examination which showed the sloughing of the endothelial cells, subintimal hyperplasia and fibrosis on the media and adventitia of femoral arteries. The histologic changes of the femoral veins were mild and not typical. But the effects of hyperbaric oxygen therapy after irradiation was seen not marked difference in irradiation group.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• 제26권4호
• /
• pp.355-362
• /
• 2000

Neoplastic growth is characterized by alterations of oncogenes and antioncogenes. The interaction between activated oncogenes and functional deletion of antioncogene appears to be the driving force directing normal cells to uncontrolled growth resulting in tumor. In addition to those genes mentioned, other genes controlling the entry of cells into the cell cycle have recently been implicated in cancer development. The overexpression of the cyclin D1 gene, which has been mapped to 11q13, either by gene rearrangement or amplification has been noted in various malignant tumors. The product of the cyclin D1 gene forms a complex with cyclin-dependent protein kinases(CDK4) that governs a key transition in the cell cycle. The relationships between the overexpression of cyclin D1 assessed by immunihistochemistry and the amplification of the cyclin D1 gene by differential polymerase chain reaction(DPCR) using primers for dopamin D2 receptor gene in 13 cases of squamous cell carcinomas of the oral cavity have been studied. The semiquantitative assay of cyclin D1 amplification has been made by cyclin D1/dopamin D2 receptor(CD/DR) ratio. The results were as follows; 1. In the normal tissue and the tumor, the CD/DR ratios were 0.82 and 1.36 respectively. This implicates 1.65-fold amplification of cyclin D1 gene in tumor compared to that in normal tissue. 2. The tumor tissue which showed overexpression of cyclin D1 by immunohistochemistry revealed 2-fold amplification of cyclin D1 compared to the normal tissue. 3. The tumor tissue which showed mild expression of cyclin D1 by immunihistochemistry revealed 1.7-fold amplification of cyclin D compared to the normal tissue. 4. The cyclin D1 was overexpressed in the tumor tissue at the rate of 38%. Above results suggest that cyclin D1 has close correlation with the development of carcinoma in the oral cavity. But further studies were needed to elucidate the carcinogeneic mechanisms by comparative studies among cyclin D1, pRb and p53.

• Journal of the Korean Association of Oral and Maxillofacial Surgeons
• /
• 제26권6호
• /
• pp.581-590
• /
• 2000

Alterations in the cellular genome affecting the expression or function of genes controlling cell growth and differentiation are considered to be the main cause of cancer. Over 30 oncogenes can be activated by insertional mutagenesis, single point mutations, chromosomal translocations and gene amplification. The ras oncogenes have been detected in $15{\sim}20%$ of human tumors that include some of the most common forms of human neoplasia and are known to acquire their transforming properties by single point mutations in two domains of their coding sequences, most commonly in codons 12 and 61. The ras gene family consists of three functional genes, N-ras, K-ras and H-ras which encode highly similar proteins of 188 or 189 amino acid residues generically known as P21. ras proteins have been shown to bind GTP and GTP, and possess intrinsic GTPase activity. Experimental study was performed to observe the mutational change of the ras gene family and apply the results to the clinical activity. 36 Golden Syrian Hamster each weighing $60{\sim}80g$ were used and painted with 0.5% DMBA by 3 times weekly on the right buccal cheek(experimental side) for 6, 8, 10, 12, 14 and 16 weeks. Left buccal cheek (control side) was treated with mineral oil as the same manner of the right side. The hamsters were sacrificed on the 6, 8, 10, 12, 14 & 16 weeks. Normal and tumor tissues from paraffin block were completely dissected by microdissection and DNA from both tissue were isolated by proteinase K/phenol/chloroform extraction. Segments of the K-ras and H-ras gene were amplified by PCR using the oligonucleotide primers corresponding to the homologous region (codon 12 and 61) of the hamster gene, and then confirmational change of ras genes was observed by SSCP and autosequencing analysis. The results were as follows : 1. Malignant lesion could be found in the experimental side from the experimental six weeks. 2. One hamster among six showed point mutation of the H-ras codon 12($G{\rightarrow}A$ transition) at the experimental 10 and 14 weeks. 3. One of six at 6 weeks, two of six at 8 weeks and one of six at 12 weeks revealed the confirmational change of the H-ras codon 61($A{\rightarrow}T$ transversion). 4. The incidence of point mutation of H-ras codon 12 and 61 were 5.5%(2 of 36) and 11%(4 of 36) respectively. 5. Point mutation of the K-ras could not be seen during the whole experimental period. Form the above results, these findings strongly support the concept that H-ras oncogenes may have the influence of the DMBA induced carcinoma of hamster buccal pouch.

• Asian Pacific Journal of Cancer Prevention
• /
• 제14권1호
• /
• pp.419-422
• /
• 2013

Conventional classifications of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) are rather unsatisfactory because of the variation in survival within each subgroup. Molecular markers are being found able to predict patient outcome in more and more tumours. The aim of this study was to characterize the expression of the proteins cyclin D1, cyclin E and P53 in GEP-NETs and assess any prognostic impact. Tumor specimens from 68 patients with a complete follow-up were studied immunohistochemically for cyclin D1, cyclin E and P53 expression. High cyclin D1 and cyclin E immunostaining (${\geq}$ 5% positive nuclei) was found in 48 (71%) and 24 (35%) cases, and high P53 staining (${\geq}$ 10% positive nuclei) in 33 (49%). High expression of P53 was more common in gastric neuroendocrine tumors and related to malignant behavior, being associate with a worse prognosis on univariate analysis (RR=1.9, 95%CI=1.1-3.2). High expression of cyclin E was significantly associated with shorter survival in the univariate analysis (RR=2.0, 95%CI=1.2-3.6) and multivariate analysis (RR=2.1, 95%CI=1.1-4.0). We found no significant correlation between the expression of cyclin D1 and any clinicopathological variables. Our study indicated a prognostic relevance for cyclin E and P53 immunoreactivity. Cyclin E may be an independent prognostic factor from the 2010 WHO Classification which should be evaluated in further studies.